Contineum Therapeutics (CTNM) Tax Rate (2023 - 2024)
Contineum Therapeutics (CTNM) posted quarterly Tax Rate of 61.0% for Q4 2024, up 11491.0% year-over-year from N/an in Q1 2024, and up 213.16% quarter-over-quarter from 53.91% in Q4 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Tax Rate (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Tax Rate history runs 2 years deep, the most recent figure standing at 61.0% for Q4 2024.
- In Q4 2024, Tax Rate rose 11491.0% year-over-year to 61.0%; the TTM figure through Dec 2024 stood at 21.03% (down 6.0% YoY), while the FY2024 annual figure was 21.03%, down 6.0% from the prior year.
- Tax Rate for Q4 2024 stood at 61.0%, up from 53.91% in the prior quarter.
- The five-year high for Tax Rate was 61.0% in Q4 2024, with the low at 53.91% in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 20.98% |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 15.11% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -10.89% |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -1.96% |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 24.15% |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 7.49% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -16.71% |
| 10 | Contineum Therapeutics | 631.90 Mn | 631.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 61.00% |
| Dec 31, 2023 | -53.91% |
| Sep 30, 2023 | 1.85% |
| Jun 30, 2023 | 1.72% |